^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Castration-Resistant Prostate Cancer

    Associations

    News

    Trials
    2d
    A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Aragon Pharmaceuticals, Inc. | Completed --> Active, not recruiting | Trial completion date: Oct 2024 --> Dec 2027
    Enrollment closed • Trial completion date
    |
    apalutamide • midazolam hydrochloride
    3d
    Multi-omics Precision Subtyping and Treatment for Prostate Cancer (ChiCTR2500115356)
    P=N/A, N=300, Not yet recruiting, Zhejiang Provincial People's Hospital; Zhejiang Provincial People's Hospital
    New trial
    3d
    Efficacy and Safety of Gemcitabine Combined with Toripalimab in Docetaxel-Refractory or -Intolerant Patients with Metastatic Castration-Resistant Prostate Cancer: A Prospective, Open-Label, Single-Arm Interventional Study (ChiCTR2500115002)
    P=N/A, N=43, Not yet recruiting, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
    New trial
    |
    gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi)
    3d
    A comparative study on the kinetic parameters imaging and radiation dosimetry of different PSMA probes labeled with copper-64 in patients with prostate cancer (ChiCTR2500114934)
    P=N/A, N=20, Recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New trial
    3d
    A real-world study of 177Lu-PSMA-617 in the treatment of mCRPC (ChiCTR2500114390)
    P=N/A, N=20, Not yet recruiting, Shanghai General Hospital; Shanghai General Hospital
    New trial
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    3d
    An Exploratory Study of 177Lu-PSMA-617 in Combination with 177Lu-TBM-001 for the Treatment (Cocktail Therapy) of Metastatic Chemoresistant Prostate Cancer (mCRPC) (ChiCTR2500113787)
    P=N/A, N=30, Recruiting, West Southwest Medical University Affiliated Hospital; West Southwest Medical University Affiliated Hospital
    New trial
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    3d
    Study on the efficacy and safety of abiraterone acetate tablets (II) + ADT + chemotherapy in first-line treatment of mCRPC (ChiCTR2500111854)
    P4, N=36, Not yet recruiting, Affiliated Hospital of Guizhou Medical University; Affiliated Hospital of Guizhou Medical University
    New P4 trial
    |
    docetaxel • abiraterone acetate • prednisone
    3d
    A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ- 78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer (ChiCTR2600117636)
    P3, N=663, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P3 trial
    |
    pasritamig (JNJ-8343)
    3d
    A prospective study of bipolar androgen followed by novel AR inhibitors combined with PD-1 inhibitors in the treatment of mCRPC (ChiCTR2600116595)
    P3, N=30, Recruiting, Beijing Hospital; Beijing Hospital
    New P3 trial
    |
    AiRuiKa (camrelizumab)
    3d
    Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) (ChiCTR2600117391)
    P3, N=800, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P3 trial
    |
    docetaxel • pasritamig (JNJ-8343)
    3d
    Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer. (PubMed, J Immunother Cancer)
    PKMYT1 is a pivotal dual regulator of tumor progression and immune evasion in CRPC. Our findings provide a compelling preclinical rationale for targeting PKMYT1 as a novel strategy to reprogram the tumor immune microenvironment and overcome resistance to immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • STING (stimulator of interferon response cGAMP interactor 1) • PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1)
    4d
    Drastic Response to Olaparib in a Patient With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA2 Alterations and Near-Threshold Tumor Mutational Burden. (PubMed, IJU Case Rep)
    Over 3 months, MRI showed further regression of the primary lesion and nodal disease, and PSA and SCC decreased. In metastatic CRPC harboring a BRCA2 mutation and near-threshold TMB, olaparib produced clear radiological and serological responses.
    Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker
    |
    TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset)
    |
    TMB-H
    |
    Lynparza (olaparib)